Advertisement

Biomedical Microdevices

, 20:93 | Cite as

Dose calculation of radioactive nanoparticles: first considerations for the Design of Theranostic Agents

  • Ralph Santos-OliveiraEmail author
  • Michael G. Stabin
Article
  • 67 Downloads

Abstract

The use of radioactive nanoparticles as imaging and therapeutic agents is increasing globally. Indeed, the use of these nanoparticles as perfect theranostic agent is highly anticipated in the pharmaceutical market. Among the radioactive nanoparticles, liposomes, solid lipid nanoparticles and polymeric nanoparticles are the most studied. However little information among adverse reactions, absorbed dose and correct dose to achieve the theranostic goal in a translational application is available. We developed a radioactive polymeric nanoparticle and calculated the absorbed dose in animal model (Wistar rats) using the OLINDA/EXM program. The results showed that some nanoparticle were uptake in five organs and minor elimination through the gastrointestinal and urinary pathways. The data corroborates the safe use in terms of blood-brain barrier and did not show high uptake by liver. The dosimetry data support the safe use of radioactive nanoparticles as theranostic agent.

Graphical abstract

Keywords

Nanoparticles Absorbed dose Theranostics Safety 

References

  1. D.S. Abou, J.E. Pickett, D.L. Thorek, Nuclear molecular imaging with nanoparticles: Radiochemistry, applications and translation. Br. J. Radiol. 88(1054), 20150185 (2015 Oct)CrossRefGoogle Scholar
  2. S. Albernaz Mde, C.A. Ospina, A.M. Rossi, R. Santos-Oliveira, Radiolabelled nanohydroxyapatite with 99mTc: Perspectives to nanoradiopharmaceuticals construction. Artif Cells Nanomed Biotechnol. 42(2), 88–91 (2014)CrossRefGoogle Scholar
  3. B.F. Coelho, M. de Souza Albernaz, A. Iscaife, K.R. Moreira Leite, M. de Souza Junqueira, E.S. Bernardes, E.O. da Silva, R. Santos-Oliveira, Nanoradiopharmaceuticals for bone Cancer metastasis imaging. Curr. Cancer Drug Targets 15(5), 445–449 (2015)CrossRefGoogle Scholar
  4. M. de Souza Albernaz, S.H. Toma, J. Clanton, K. Araki, R. Santos-Oliveira, Decorated superparamagnetic Iron oxide nanoparticles with monoclonal antibody and diethylene-Triamine-Pentaacetic acid labeled with Thechnetium-99m and Galium-68 for breast Cancer imaging. Pharm. Res. 35(1), 24 (2018)CrossRefGoogle Scholar
  5. N. Drude, L. Tienken, F.M. Mottaghy, Theranosticand nanotheranostic probes in nuclear medicine. Methods 130, 14–22 (2017)CrossRefGoogle Scholar
  6. European Nuclear Society, Radiation exposure, dose limits, Germany (n.d.), http://www.euronuclear.org/info/encyclopedia/r/radiation-exposure-dose-limit.htm. Accessed 12 Dec 2017
  7. J. Hu, Y. Sheng, J. Shi, B. Yu, Z. Yu, G. Liao, Long circulating polymeric nanoparticles for gene/drug delivery. Curr Drug Metab (2017).  https://doi.org/10.2174/1389200219666171207120643
  8. J.V. Jokerst, S.S. Gambhir, Molecular imaging with theranostic nanoparticles. AccChem Res. 44(10), 1050–1060 (2011)CrossRefGoogle Scholar
  9. T.B. Ligiero, C. Cerqueira-Coutinho, M.S. Albernaz, M. Szwed, E.S. Bernardes, M.A.V. Wasserman, R. Santos-Oliveira, Diagnosing gastrointestinal stromal tumours by single photon emission computed tomography using nano-radiopharmaceuticals based on bevacizumab monoclonal antibody. BPEX 2, 045017–045019 (2016)Google Scholar
  10. L. Pascual, C. Cerqueira-Coutinho, A. García-Fernández, B. de Luis, E.S. Bernardes, M.S. Albernaz, S. Missailidis, R. Martínez-Máñez, R. Santos-Oliveira, M. Orzaez, F. Sancenón, MUC1 aptamer-capped mesoporous silica nanoparticles for controlled drug delivery and radio-imaging applications. Nanomedicine 13(8), 2495–2505 (2017)CrossRefGoogle Scholar
  11. S.R. Pinto, M.A. Sarcinelli, M.S. Albernaz, F.M.R. Da Silva, S.H. Seabra, P.A. Nascimento, C.L.G. Carvalho, R. Santos-Oliveira, In vivo studies: Comparing the administration via and the impact on the biodistribution of radiopharmaceuticals. Nucl. Med. Biol. 41, 772–774 (2014)CrossRefGoogle Scholar
  12. R. Salvi, C. Cerqueira-Coutinho, E. Ricci-Junior, S.N. Dos Santos, S.R. Pinto, E.S. Bernardes, P.L. Barros de Araujo, R. Santos-Oliveira, Diagnosing lung cancer using etoposide microparticles labeled with 99mTc. Artif Cells NanomedBiotechnol. 30, 1–5 (2017)Google Scholar
  13. R. Santos-Oliveira, Nanoradiopharmaceuticals: Is that the future for nuclear medicine? CurrRadiopharm. 4(2), 140–143 (2011)Google Scholar
  14. M.G. Stabin, J.A. Siegel, RADAR dose estimate report: A compendium of radiopharmaceutical dose estimates based on OLINDA/EXM version 2.0. J. Nucl. Med. 59, 154–160 (2018) published ahead of print September 8, 2017CrossRefGoogle Scholar
  15. X. Sun, W. Cai, X. Chen, Positron emission tomography imaging using radiolabeled inorganic nanomaterials. AccChem Res. 48(2), 286–294 (2015)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Brazilian Nuclear Energy CommissionNuclear Engineering InstituteRio de JaneiroBrazil
  2. 2.Laboratory of Radiopharmacy and NanoradiopharmaceuticalsZona Oeste State UniversityRio de JaneiroBrazil
  3. 3.Department of Radiology and Radiological SciencesVanderbilt UniversityNashvilleUSA

Personalised recommendations